1
2
The potential of low molecular weight heparin to mitigatie cytokine storm in severe covid-19 patients: a retrospective clinical study

Chen Shi#, Cong Wang#, Hanxiang Wang#, Chao Yang, Fei Cai, Fang Zeng, Fang Cheng, Yihui Liu,
Taotao Zhou, Bin Deng, Jinping Li, Yu Zhang*

#Contributed equally

*Corresponding author

Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science
and Technology, Wuhan, China; Hubei Province Clinical Research Center for Precision Medicine for
Critical Illness, Wuhan, China (C Shi PhD, Y Zhang PhD); Department of Pharmacy, Union Hospital,
Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (C Wang MD,
H Wang MD, F Zeng MD, F Cheng MD, Y Liu PhD, T Zhou MD, B Deng PhD); Department of

Medical Biochemistry and Microbiology , Uppsala University, Uppsala, Sweden (J Li PhD);

Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China (C Yang MD, F Cai MD)

Correspondence to:

Prof Yu Zhang PhD, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, 430000, China, whxhzy@163.com

Summary:

Background On March 11, 2020, the World Health Organization declared its assessment of COVID-19

as a global pandemic. Effective therapeutic drugs are urgently needed to improve the overall prognosis

of patients, but currently no such drugs are available.

Methods The basic information, complete blood count, coagulation profile, inflammatory cytokines

and serum biochemical indicators in 42 patients with COVID-19 (21 of whom were treated with low

molecular weight heparin (LMWH), and 21 without LMWH) were retrospectively analyzed to compare

and evaluate the effect of LMWH treatment on disease progression.

Findings 42 patients with COVID-19 treated at the hospital between February 1 and March 15, 2020

were selected for the study, of which 21 underwent LMWH treatment (Heparin group), and 21 did not (Control), during hospitalization. The changes in lymphocyte% in patients in the heparin group before and after LMWH treatment were significantly different to those in the control group (11.10±9.50, 3.08±9.66, p=0.011). The changes in D-dimer and fibrinogen degradation products (FDP) levels in the heparin group before and after LMWH treatment were significantly different to those in the control group (-2.85±3.90, -0.05±0.85, p=0.002; -9.05±13.14, -1.78±3.15, p=0.035). In the heparin group, IL-6 levels were significantly reduced after LMWH treatment (47.47±58.86, 15.76±25.71, p=0.006). In addition, the changes in IL-6 levels in the heparin group before and after LMWH treatment were significantly different to those in the control group (-32.46±65.97, 14.96±151.09, p=0.031).

Interpretation In this study, we found that LMWH can improve the coagulation dysfunction of COVID-19 patients, and has anti-inflammatory effects of reducing IL-6 and increasing lymphocyte%, which can be used as a potential therapeutic drug for the treatment of COVID-19 and provide guidance for subsequent clinical treatment.

Introduction

According to *Nature*, the spread of coronavirus disease 2019 (COVID-19) is becoming unstoppable.[1] On March 11, 2020, the World Health Organization (WHO) declared its assessment of COVID-19 as a global pandemic. SARS-CoV-2 is characterized by a long incubation period, high infectivity, and multiple routes of transmission.[2,3] According to real-time WHO statistics, the total number of confirmed cases of COVID-19 worldwide as of April 1, 2020 has exceeded 850,000, with more than 40,000 deaths. However, no effective medicines are currently available, and it can only be treated symptomatically. Given the rapid spread of COVID-19 and the high mortality rate in severe cases, there is an urgent need for a better understanding of its clinical characteristics and may help to screen out reliable specific drugs from marketed drugs.

Lymphopenia and inflammatory cytokine storms are typical abnormalities observed in highly pathogenic coronavirus infections (such as SARS and MERS),[10] and are believed to be associated with disease severity.[5-7] Several clinical studies have observed that cytokine storms are important mechanisms of disease exacerbation and death in COVID-19 patients, .[5-7] Particularly, IL-6 levels in severely ill patients were significantly higher than that in mild cases.[8] IL-6 is one of the core cytokines that are consistently found to be elevated in serum of patients with cytokine storm,[9] it contributes to many of the key symptoms of cytokine storm, i.e. vascular leakage, and activation of the complement

and coagulation cascade inducing disseminated intravascular coagulation (DIC).[10,11] The level of IL-6

is closely related to the occurrence and severity of cytokine storms,reducing the level or activity of IL-6

may contribute to prevent or even reverse the cytokine storm syndrome caused by the virus, [12] thereby

improving the condition of patients with COVID-19.

In recent years, a large number of studies have revealed that low molecular weight heparin (LMWH)

has various non-anticoagulant properties[13] that play an anti-inflammatory role by reducing the release

and biological activity of IL-6.[14-16] However, the anti-inflammatory effects of LMWH in COVID-19

are not currently known. To the best of our knowledge, this is the first retrospective cohort study, to

analyze the relieving effect of LMWH in patients with COVID-19. This study aims to review and

analyze the treatment course of patients with COVID-19 to investigate the anti-inflammatory effects of

heparin and delay disease progression to provide guidance for subsequent clinical practice(Fig.1).

Methods

Research subjects

To investigate the therapeutic effect of LMWH on COVID-19, we conducted a retrospective study. All

cases in this study were located at Union Hospital, Tongji Medical College, Huazhong University of

Science and Technology (Wuhan, Hubei Province, China), a designated treatment hospital for patients

with COVID-19. This study was approved by the institutional review board of the hospital. In total, we

retrospectively collected the electronic medical records of 42 patients with COVID-19, the admission

data for these patients was from February 1, 2020, to March 15, 2020 (Fig.2 shows the case inclusion

flowchart), of which 21 underwent LMWH treatment (Heparin group, Table 1), and 21 did not

(Control), during hospitalization.

Inclusion criteria: (1) met the diagnostic standards of novel coronavirus pneumonia (7th edition)

formulated by the National Health Commission of China; (2) experienced any of the following:

shortness of breath, respiration rate(RR) ≥ 30 breaths/minute; resting oxygen saturation ≤ 93%;

PaO2/FiO2 ≤ 300 mmHg; lung imaging showing significant lesion progression by > 50% within

24-48 h, and a severe clinical classification; (3) age ≥ 18 years; (4) no previous history of

bronchiectasis, bronchial asthma, or other respiratory diseases; (5) no immunosuppressant or

glucocorticoid use during treatment.

Exclusion criteria: (1) patients with severe systemic diseases and other acute or chronic infectious

diseases; (2) patients with liver and kidney insufficiency or congenital heart disease; (3) patients who

had been treated with LMWH in the previous three months; (4) patients with a previous history of
mental illness; (5) pregnant or lactating women; (6) patients clinically classified as critically ill or
housed in the intensive care unit (ICU); (7) patients allergic to LMWH or contraindicated for LMWH.

Data collection

The basic information, complete blood count, coagulation profile, inflammatory cytokines and serum
biochemical indicators (including liver function, kidney function, lactate dehydrogenase, C-reactive
protein (CRP) and electrolytes) in 42 patients with COVID-19 were retrospectively analyzed. Two
researchers also independently reviewed the data collection forms to double check the data collected.

Statistical analysis

Data analysis was performed using SPSS 22.0 statistical software. Data were expressed as mean ±
standard deviation (SD). GraphPad 6.0 software was used for plotting. Differences between groups
were evaluated using the T-test for measurement data, the Chi-square test for count data, and the
Kruskal-Wallis nonparametric test between groups (independent samples) and within groups (related
samples). Differences of $p < 0.05$ were considered statistically significant.

Results

General characteristics of patients with COVID-19

As shown in Table 2, the heparin group consisted of 13 males and eight females aged between 42 and
91 years (median age was 69.0 years), and the control group consisted of 14 males and seven females
aged between 40 and 84 years (median age was 69.0 years); there was no significant difference
between the two groups. There were no significant differences in comorbidities, such as hypertension,
diabetes, cardiovascular disease, and carcinomas, between the two groups. Similarly, there were no
significant differences in novel coronavirus pneumonia onset symptoms, including fever (body
temperature ≥ 37.3°C), cough, sputum, chest distress or asthma, myalgia, fatigue, anorexia, diarrhea,
and nausea and vomiting. Similarly, there was no significant difference in antiviral treatment between
the two groups. These results indicate that the general characteristics of the two groups of patients were
consistent and comparable.

LMWH has no effect on the days to conversion to negative and the duration of hospitalization of
patients with COVID-19

As shown in Table 2, the number of days to conversion to negative (time from hospitalization to virus
shedding) was 20.0 days (IQR 11.0-31.0) in the heparin group and 19.0 days (IQR 12.0-30.0) in the

control group (p = 0.46); the difference between the two groups was not significant. Similarly, the
length of hospital stay was 29.0 days (IQR 17.0-42.0) in the heparin group and 27.0 days (IQR
24.0-31.0) in the control group (p = 0.41); the difference between the two groups was not significant.
Notably, all patients showed improvement after treatment.

Effect of LMWH on Blood routine in patients with COVID-19

As shown in Fig.3A-D, there was no significant difference in red blood cells (RBC), white blood cells
(WBC), monocyte% and neutrophil% levels between the two groups. As shown in Fig.3E, there was no
significant difference in lymphocyte% between the heparin and control groups before treatment (18.84
±8.24, 22.42±8.74, p=0.144). There was no significant difference in lymphocyte% between the heparin
and control groups after treatment (29.94±7.92, 25.65±10.10, p=0.215). However, patients in the
heparin group had a significantly increased percentage of lymphocytes after LMWH treatment (18.84±
8.24, 29.94±7.92, p=0.000). In addition, the changes in lymphocyte% in patients in the heparin group
before and after LMWH treatment were significantly different to those in the control group (11.10±
9.50, 3.08±9.66, p=0.011).

Effect of LMWH on coagulation function in patients with COVID-19

According to the data, there was no significant difference in thrombin time (TT, Fig.3F), activated
partial thromboplastin time (APTT, Fig.3G), prothrombin time (PT, Fig.3H) levels between the two
groups. As shown in Fig.3I, the levels of D-dimer in the heparin group were significantly higher
compared to those in the control group before treatment (3.75±4.04, 1.23±1.15, p=0.009). There was
no significant difference in D-dimer levels between the heparin and control groups after treatment (0.90
±0.44, 1.00±1.06, p=0.368). In the heparin group, D-dimer levels were significantly reduced after
LMWH treatment (3.75±4.04, 0.90±0.44, p=0.001). The changes in D-dimer levels in patients in the
heparin group before and after LMWH treatment were significantly different to those in the control
group (-2.85±3.90, -0.05±0.85, p=0.002). As shown in Fig.3J, the levels of fibrinogen degradation
products (FDP) in the heparin group were significantly higher compared to those in the control group
before treatment (14.35±14.6, 4.05±3.9, p=0.002). There was no significant difference in FDP levels

between the heparin and control groups after treatment (2.64±1.16, 3.59±4.00, p=0.959). In the heparin

group, FDP levels were significantly reduced after LMWH treatment (14.35±14.6, 2.64±1.16, p=0.001).

The changes in FDP levels in patients in the heparin group before and after LMWH treatment were

significantly different to those in the control group (-9.05±13.14, -1.78±3.15, p=0.035). However, there

was no significant difference in fibrinogen (FIB, Fig.3K), antithrombin Ⅲ (AT Ⅲ, Fig.3L) and

international normalized ratio (INR, Fig.3M) levels between the two groups.

Effect of LMWH on CRP in patients with COVID-19

As shown in Fig.3N, there were no significant differences in CRP levels between the two groups of

patients before treatment (31.15±26.62, 29.00±23.79, p=0.497). There were no significant differences

in CRP levels between the two groups of patients after treatment (8.95±10.44, 8.76±16.66, p=0.620).

Similarly, there were no significant differences in the changes of CRP levels between the two groups of

patients before and after LMWH treatment (-22.62±23.79, -20.23±33.91, p=0.660).

Effect of LMWH on cytokines in patients with COVID-19

As shown in Fig.4, we performed statistical analyses on the levels of inflammatory cytokines in the two

groups. There were no significant differences in the levels of IL-2, IL-4, IL-10, TNF-α and IFN-γ

between the two groups. Notably, there was no significant difference in IL-6 levels between the heparin

and control groups before treatment (47.47±58.86, 63.27±96.27, p=0.950). The levels of IL-6 in the

heparin group were significantly lower compared to those in the control group after treatment (15.76±

25.71, 78.24±142.41, p=0.000). In the heparin group, IL-6 levels were significantly reduced after

LMWH treatment (47.47±58.86, 15.76±25.71, p=0.006). Similarly, the changes in IL-6 levels in the

heparin group before and after LMWH treatment were significantly different to those in the control

group (-32.46±65.97, 14.96±151.09, p=0.031).

Discussion

Cytokine storms are associated with deterioration in several infectious diseases, including SARS and

avian influenza,[4.17] and are an important mechanism of exacerbation in patients.[18] In recent years,

studies have revealed that heparin has various non-anticoagulant properties, for instance LMWH can

exert anti-inflammatory effects by reducing the release and biological activity of IL-6.[14-16,19]

Meanwhile some results indicate that IL-6 and IL-8 can cause hypercoagulation, leading to scattered

fibrin clots, shortening the clot dissolution time and maximum dissolution rate.[20] Several clinical

researches have observed that severe COVID-19 patients had higher levels of IL-6,[8] which suggests the

hypercoagulation status of COVID-19 patients may be related to the body increased cytokine levels. In

previous studies of patients with COVID-19, D-dimer levels were significantly elevated in patients

admitted to the ICU with severe cases.[21] The research of Ning Tang et al. showed higher levels of

D-dimer and FDP in fatal cases,[22] and Li *et al.* believe that while monitoring for venous

thromboembolism, there may have some correlation between D-dimer and COVID-19 severity.[23]

However, there is currently no conclusive evidence supporting the use of D-dimer as an evaluation

index.[24-26] A large sample analysis is required to determine whether D-dimer is associated with

COVID-19 severity. Therefore, the present study does not consider this parameter as an evaluation

index for disease progression. The average values of D-dimer and FDP before treatment was greater in

the heparin group than in the control group (3·75,1·23,P < 0.01;14·35,4·05,P < 0·01). Because this trial

is a retrospective analysis, we did not intervene in the drug use of the patients, it can be inferred that

the purpose of medication in the heparin group is to improve hypercoagulability. Because D-dimer and

FDP are not considered as factors for the patient's disease progression, therefore, it has no effect on

subsequent analysis of results.

Several studies have recommended CRP and lymphocyte%(LYM%)as indices for evaluating the

effectiveness of clinical drugs or treatments.[27-29] In the difference analysis of this study, there was no

statistically significant difference in CRP between the groups, indicating that LMWH treatment has no

effect on this parameter, but in the result of LYM%, the mean value of the heparin group was higher

than that of the control group (11·10% and 3·08%, respectively). LYM% was higher in the heparin

group after treatment compared to the control group ($p < 0·001$), which is consistent with the results of

Derhaschnig *et al.*[30] This suggests that LMWH can increase LYM% in patients with COVID-19 and

improve their condition. There are two possible reason: First, SARS-CoV-2 is highly homologous to

SARS-CoV, heparan sulfate proteoglycans(HSPGs) is the basic cell surface molecule involved in

SARS-CoV cell entry,[31] and LMWH is a member of the HSPGs family,[32] it has already been confirmed

that the addition of exogenous heparin reduced the ability of SARS-CoV to bind to the cell surface and

increased cellular resistance to infection.[33,34] Mycroft-West *et al.* also showed that LMWH can bind to

the SARS-CoV-2 surface protein (Spike) S1 receptor binding domain and block the replication of the

virus, thus, showing potential antiviral effects.[35] Additionally, LMWH can reduce lymphocyte death

caused by the direct viral infection of lymphocytes.[6] The second, preliminary research has confirmed

that proinflammatory cytokines, such as TNFα and IL-6, can induce lymphopenia.[7] Therefore,

decreases in the number or activity of relevant inflammatory factors may have some significance for
the increase in LYM%.

IL-6 levels in severely ill patients with COVID-19 are significantly higher than in patients with mild
cases,[8] and a cytokine storm may occur when cytokines reach a certain threshold in the body.[9] The
transition from a mild to severe condition in patients with COVID-19 may be caused by cytokine
storms. Reducing IL-6 release or activity may prevent the cytokine storm syndrome caused by the
virus,[10] thereby improving the condition of patients with COVID-19. Studies have shown that LMWH
may reduce the release of IL-6 in the body by inhibiting the expression of nuclear factor κB
(NF-κB).[14-16] In the present study, we performed statistical analysis of the levels of inflammatory
cytokines in two groups of patients, and the results showed that IL-6 significantly decreased in the
heparin group compared to the control group, whereas the changes in other inflammatory factors were
not statistically significant; these results are consistent with the conclusions above. In addition, a study
by Mummery *et al.* found that heparincan bind to IL-6, it may serve to reduce the availability of IL-6 to
its receptor complex, including IL-6 binding to SIL-6R and IL-6 /SIL-6R binding to sgp130,[19] this may
reduce the the biological activity of IL-6. This indicates that LMWH reduces the release of IL-6 while
also reducing its biological activity, which also explains the increase of LYM% in the heparin group.

This study found that LMWH can improve the coagulation dysfunction of COVID-19 patients, and has
anti-inflammatory effects of reducing il-6 and increasing LYM%, which can be used as a potential
therapeutic drug for the treatment of COVID-19 and provide guidance for subsequent clinical treatment.
In addition, to further confirm the conclusions of this study, we conducted a prospective clinical study
to evaluate the efficacy and safety of enoxaparin sodium in the treatment of hospitalized adult patients
with COVID-19(Chinese Clinical Trial Registry ,number:chiCTR2000030700), with the expectation of
providing a more powerful reference for treatment.

Limitations:

This study has some limitations. First, due to the retrospective design, we were unable to control the
time intervals between examinations of various indices in patients and the LMWH dosing schedule,
and we could not estimate the effective dose and timing of LMWH. Second, there were no critical
cases in the two groups of patients in the trial; the treatment outcome of all cases was improvement and
discharge and there were no deaths. Therefore, the reference value for the treatment outcomes of
critically ill patients was limited. Finally, the sample size and single-center design may have limited our
findings.

Contributors

CS, JP and YZ conceptualized and designed the study, and CS and YZ had full access to all data, and

took responsibility for data integrity and accuracy of the analysis. CS, CW and HX wrote the

manuscript. CY, FC and FZ reviewed the manuscript. FC, YH, TT and BD performed the statistical

analysis. All authors contributed to data acquisition, analysis and interpretation, and approved the final

version for submission.

Declaration of interests

All authors declare no competing interests.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81603037 to SC)

and the National Key Research and Development Plan of China(2017YFC0909900).

Patient consent for publication   Not required

Ethics approval   The human study was approved the Research Ethics Committee of Union Hospital,

Tongji Medical College, Huazhong University of Science and Technology.

References:

1.   Callaway E. Time to use the p-word? Coronavirus enter dangerous new phase. Nature 2020; 579:

12.

2.   Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern.

Lancet. 2020, 395(10223):470-473.

3.   Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel

coronavirus in Wuhan, China. Lancet. 2020, 395(10223):497-506.

4.   De Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into

emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–534.

5.   Zhou W, Liu YS, Tian DD, et al. Potential benefits of precise corticosteroids therapy for severe

2019-nCoV pneumonia. Signal Transduction and Targeted Therapy. 2020;5:18.

6.   Li Tan, Qi Wang, Duanyang Zhang, et al. Lymphopenia predicts diseaseseverity of COVID-19:a

descriptive and predictive study. MedRxiv.2020.03.01.20029074.

7.   Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6

and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol. 2002;169(8):

4288-97.

8.   Wan SX, Yi QJ, Fan SB, et al. Characteristics of lymphocyte subsets and cytokines in peripheral
blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv.
2020[2020-02-24].

9.   Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J
Immunother Cancer. 2018;6(1):56.

10.   Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for
cytokine storm. Immunotherapy. 2016;8(8):959-970.

11.   Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol.
2015;16:448-457.

12.   Teachey DT, Lacey SF, Shaw PA, et al. Identification of Predictive Biomarkers for Cytokine
Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic
Leukemia. Cancer Discov. 2016;6(6):664-679.

13.   Wang QL, Shang XY, Zhang SL, et al. Effects of inhaled low molecular weight heparin on airway
allergic inflammation in aerosol-ovalbumin-sensitized guinea pigs. Jpn J Pharmacol.
2000;82(4):326-330.

14.   Qian Y, Xie H, Tian R, Yu K, Wang R. Efficacy of low molecular weight heparin in patients with
acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. COPD.
2014;11(2):171-176.

15.   Yina Liu, Shengtian Mu, Xu Li, Yingjian Liang, Liang Wang, Xiaochun Ma. Unfractionated
Heparin Alleviates Sepsis-Induced Acute Lung Injury by Protecting Tight Junctions. J Surg Res.
2019;6(238): 175-185.

16.   Li X, Ma Y, Chen T, Tang J, Ma X. Unfractionated heparin inhibits lipopolysaccharide-induced
expression of chemokines in human endothelial cells through nuclear factor-κB signaling pathway.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016;28(2):117-121.

17.   Dongmei Rao. Research progress on cytokine storm induced by pathogen infection. Medical
Information. 2014;27(2):480-481.

18.   Qian Chen, Yao Wang, Fangzhou Jiao, et al. Discussion on the mechanism and intervention
strategy of inflammatory storm of new coronavirus pneumonia. Chinese Journal of Infectious
Diseases. 2020;38(2020-02-26).

19.   Mummery RS, Rider CC. Characterization of the heparin-binding properties of IL-6. J Immunol.

2000;165(10):5671-5679.

20. Bester J, Matshailwe C, Pretorius E. Simultaneous presence of hypercoagulation and increased
clot lysis time due to IL-1β, IL-6 and IL-8. Cytokine. 2018;110:237-242.

21. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus
in Wuhan, China. Lancet. 2020;395(10223):497-506.

22. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor
prognosis in patients with novel coronavirus pneumonia [published online ahead of print, 2020
Feb 19]. J Thromb Haemost. 2020;10.1111/jth.14768.

23. Li XY, Du B, Wang YS, et al. The keypoints in treatment of the critical coronavirus disease 2019
patient. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 29;43(0):E026.[Online ahead of print].

24. Querol-Ribelles JM, Tenias JM, Grau E, et al. Plasma d-dimer levels correlate with outcomes in
patients with community-acquired pneumonia. Chest. 2004;126(4):1087-1092.

25. Snijders D, Schoorl M, Bartels PC,et al. D-dimer levels in assessing severity and clinical outcome
in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical
trial. Eur J Intern Med. 2012;23(5):436-441.

26. Duarte JC, Tavares e Castro A, Silva R, et al. Prognostic value of plasma D-dimer level in adults
with community-acquired pneumonia: a prospective study. Rev Port Pneumol (2006).
2015;21(4):218-219.

27. Fei Zhou, Ting Yu, Ronghui Du, et al. Clinical course and risk factors for mortality of adult
inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar
12:S0140-6736(20)30606-1. Online ahead of print.

28. Li Tan, Qi Wang, Duanyang Zhang, et al. Lymphopenia predicts diseaseseverity of COVID-19:a
descriptive and predictive study. MedRxiv.2020.03.01.20029074.

29. Xun Li, Luwen Wang, Shaonan Yan.et al. Clinical characteristics of 25 death cases infected with
COVID-19 pneumonia: a retrospective review of medical records in a single medical center,
Wuhan, China. MedRxiv. 2020.02.25.

30. Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Hollenstein U, Panzer S, Jilma B. Evaluation
of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med.
2003;31(4):1108-1112.

31. Belting M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends in biochemical

sciences. 2003;28:145–151.

32. Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv

Carbohydr Chem Biochem. 2001;57:159–206.

33. Vicenzi E, Canducci F, Pinna D, et al. Coronaviridae and SARS-associated coronavirus strain

HSR1. Emerg Infect Dis. 2004;10(3):413-8.

34. Lang J, Yang N, Deng J, et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to

heparan sulfate proteoglycans. PLoS One. 2011;6(8):e23710.

35. Courtney Mycroft-West , Dunhao Su, Stefano Elli, et al . The 2019 coronavirus (SARS-CoV-2)

surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon

heparin binding. BioRxiv preprint.

Figure captions

Figure 1. Possible mechanism of anti-inflammatory effects of LMWH in patients with COVID-19.

Under conventional antiviral treatment regimens, LMWH improves hypercoagulability, inhibits IL-6

release, and counteracts IL-6 biological activity in patients. It has potential antiviral effects and helps

delay or block inflammatory cytokine storms. LMWH can increase the LYM% of patients and may be

suitable as treatment for COVID-19.

Figure 2. Flowchart of inclusion and exclusion criteria for patients with COVID-19.

Based on strict inclusion and exclusion criteria, 42 patients with COVID-19 treated at the hospital

between February 1 and March 15, 2020 were selected for the study, of which 21 underwent LMWH

treatment (Heparin group) and 21 did not (Control) during hospitalization.

Table 1. LMWH use in the 21 patients with COVID-19.

Details of the dose, frequency, route of administration, and days of use of LMWH in the heparin group.

Table 2. General characteristics of all the patients with COVID-19.

There were no significant differences in age, sex, comorbidities, onset symptoms, time from

hospitalization to virus shedding, length of hospital stay, antiviral treatment and disease progression

between the two groups. Data are median (IQR) or n(%). p values are comparing heparin group and

control. NA=not applicable.

Figure 3. Effect of LMWH on complete blood count, coagulation profile and CRP in patients with

COVID-19.

(A-N) Red blood cells (A), white blood cells (B), monocytes% (C), neutrophils% (D), lymphocytes%

(E), TT (F), APTT (G), PT (H), D-dimer (I), FDP (J), FIB (K), AT III (L), INR (M) and CRP (N) levels

in patients with COVID-19. Data are expressed as mean $\pm$ standard deviation (SD) (n = 21). C1 vs.

H1 or C2 vs. H2, [a] $p < 0.05$, [aa] $p < 0.01$, [aaa] $p < 0.001$; C1 vs. C2 or H1 vs. H2, [b] $p < 0.05$, [bb] $p < 0.01$, [bbb]

$p < 0.001$; C3 vs. H3, [c] $p < 0.05$, [cc] $p < 0.01$, [ccc] $p < 0.001$. (C1: control group, indices at admission; C2:

control group, indices at discharge; C3: control group, changes in indices during hospitalization; H1:

heparin group, indices before LMWH treatment; H2: heparin group, indices after LMWH treatment;

H3: heparin group, changes in indices before and after LMWH treatment.).

Figure 4. Effect of LMWH on inflammatory cytokines in patients with COVID-19.

(A-F) IL-2 (A), IL-6 (B), TNF-α (C), IL-4 (D), IL-10 (E), and IFN-γ (F) levels in the two groups of

patients with COVID-19. Data are expressed as mean $\pm$ standard deviation (SD) (n = 21). C1 vs. H1

or C2 vs. H2, [a] $p < 0.05$, [aa] $p < 0.01$, [aaa] $p < 0.001$; C1 vs. C2 or H1 vs. H2, [b] $p < 0.05$, [bb] $p < 0.01$, [bbb] p

< 0.001; C3 vs. H3, [c] $p < 0.05$, [cc] $p < 0.01$, [ccc] $p < 0.001$. (C1: control group, indices at admission; C2:

control group, indices at discharge; C3: control group, changes in indices during hospitalization; H1:

heparin group, indices before LMWH treatment; H2: heparin group, indices after LMWH treatment;

H3: heparin group, changes in indices before and after LMWH treatment.)

```
                        ┌─────────────────────────┐
                        │  Hospitalized patients  │
                        └─────────────────────────┘
```

Inclusion criteria:
① Patients were diagnosed as COVID-19 according to the New Coronavirus Pneumonia Diagnosis Program (7th edition) published by the National Health Commission of China;
② The clinical classification was severe，including any of the following: shortness of breath, RR ≥30 bpm, blood oxygen saturation ≤93% (at rest), PaO2/FiO2≤300 mmHg, or pulmonary inflammation that progresses significantly within 24 to 48 hours ＞50%;
③ Age ≥18 years old;
④ Patients with no previous respiratory diseases such as bronchiectasis and bronchial asthma;
⑤ Patients who had not received immunosuppressive agents and glucocorticoid therapy during hospitalization.

Exclusion criteria:
① Patients with severe systemic diseases and other acute/chronic infectious diseases;
② Patients with liver/kidney dysfunction and congenital heart disease;
③ Patients who received LMWH treatment within the last three months;
④ Patients with a previous history of mental illness;
⑤ Pregnant or lactating women;
⑥ Critical patients or patients requiring ICU care;
⑦ Patients with allergy to LMWH or contraindication to LMWH.

┌──┐   ┌──┐
│ Patients who received LMWH treatment during │   │ Patients who were not treated with LMWH during │
│ hospitalization（Heparin Group, n=21） │   │ hospitalization（Control, n=21） │
└──┘   └──┘

Heparin Group (n=21)	Treatment with LMWH	Days of treatment
H1	Enoxaparin sodium injection 4000AxaIU qd i.h.	10
H2	Enoxaparin sodium injection 4000AxaIU qd i.h.	10
H3	Enoxaparin sodium injection 4000AxaIU qd i.h.	14
H4	Enoxaparin sodium injection 4000AxaIU qd i.h.	13
H5	Enoxaparin sodium injection 4000AxaIU qd i.h.	17
H6	Nadroparin calcium injection 4100AxaIU qd i.h.	9
H7	Enoxaparin sodium injection 4000AxaIU qd i.h.	2
H8	LMWH sodium injection 5000IU once i.h.	1
H9	Enoxaparin sodium injection 4000AxaIU qd i.h.	16
H10	Enoxaparin sodium injection 4000AxaIU qd i.h.	19
H11	Enoxaparin sodium injection 4000AxaIU qd i.h.	14
H12	Enoxaparin sodium injection 2000AxaIU qd i.h.	19
H13	Enoxaparin sodium injection 2000AxaIU qd i.h.	22
H14	Nadroparin calcium injection 4100AxaIU qd i.h.	11
H15	Nadroparin calcium injection 4100AxaIU qd i.h.	13
H16	Enoxaparin sodium injection 4000AxaIU qd i.h.	8
H17	Nadroparin calcium injection 4100AxaIU qd i.h.	19
H18	LMWH sodium injection 5000IU qd i.h.	8
H19	Enoxaparin sodium injection 4000AxaIU qd i.h.	8
H20	Enoxaparin sodium injection 4000AxaIU qd i.h.	7
H21	Enoxaparin sodium injection 4000AxaIU qd i.h.	10

	Heparin Group (n=21)	Control (n=21)	p value
Characteristics			
Age, years	69.0(42.0-91.0)	69.0(40.0-84.0)	0.54
Sex	-	-	0.75
Female	8(38%)	7(33%)	-
Male	13(62%)	14(67%)	-
Comorbidity	13(62%)	8(38%)	0.12
Hypertension	8(38%)	5(24%)	0.32
Diabetes	6(29%)	2(10%)	0.12
Cardiovascular disease	5(24%)	2(10%)	0.21
Chronic obstructive lung disease	0	0	NA
Carcinoma	0	1(5%)	0.31
Chronic kidney disease	0	0	NA
Other	4(19%)	1(5%)	0.15
Signs and symptoms			
Fever (temperature ≥37.3℃)	15(71%)	13(62%)	0.51
Cough	9(43%)	7(33%)	0.53
Sputum	6(29%)	4(19%)	0.47
Chest distress or asthma	11(52%)	8(38%)	0.35
Myalgia	2(10%)	3(14%)	0.63
Fatigue	8(38%)	5(24%)	0.32
Anorexia	6(29%)	5(24%)	0.73
Diarrhoea	2(10%)	1(5%)	0.55
Nausea or vomiting	2(10%)	1(5%)	0.55
Respiratory rate ≥30 breaths per min	0	0	NA
Pulse ≥125 beats per min	0	0	NA
Systolic blood pressure ＜90 mmHg	0	0	NA
Antiviral therapy			
Arbidol	18(86%)	20(95%)	0.29
Recombinant Human Interferon α2B (aerosol inhalation)	6(29%)	6(29%)	1.00
Ribavirin	2(10%)	0	0.15
Lopinavir/Ritonavir	2(10%)	0	0.15
Traditional Chinese medicine decoction	11(52%)	9(43%)	0.54
Disease progression			
Improved	21(100%)	21(100%)	NA
Invariable	0	0	NA
Deteriorative	0	0	NA
Time from hospitalization to virus shedding after the onset of the COVID-19, days	20.0(11.0-31.0)	19.0(12.0-30.0)	0.46
Hospital length of stay, days	29.0(17.0-42.0)	27.0(24.0-31.0)	0.41